Tremelimumab

Feb 20, 2020

Biocare Medical Launches 7 Novel IVD Antibodies for Clinical Diagnostic and Cancer Research Applications with a Focus on Immuno-Oncology

Sep 21, 2019

2019 CSCO | CStone announces preliminary results from Phase I trial of CS1002 demonstrating characteristics comparable to ipilimumab

Oct 18, 2018

Innovent Announces First Patient Dosed in a Phase I Clinical Trial of Anti-CTLA-4 Monoclonal Antibody

Jul 09, 2018

ImaginAb Appoints James Allison, Padmanee Sharma and Ramy Ibrahim to Scientific Advisory Board

May 09, 2018

First and Only Immuno-Oncology Treatment, Imfinzi® (durvalumab), for Stage III, Unresectable Non-Small Cell Lung Cancer Now Approved in Canada

Feb 16, 2018

US FDA APPROVES IMFINZI® (DURVALUMAB) FOR UNRESECTABLE STAGE III NON-SMALL CELL LUNG CANCER

Feb 13, 2018

Phase II trial demonstrates activity of durvalumab in patients with recurrent or metastatic head and neck cancer

Dec 29, 2017

CStone's anti-CTLA-4 antibody CS1002 filed for clinical trial approval in Australia

Nov 06, 2017

Health Canada Approves IMFINZI® (durvalumab) for Previously Treated Patients with Advanced Bladder Cancer

Jun 01, 2017

Parker Institute for Cancer Immunotherapy Scientists to Present Research at ASCO 2017 on IDO Pathway Inhibitors, Novel CAR-Ts and the Microbiome's Potential in Immunotherapy